and summative scores also correlate with GPA in the preclinical period.

Acknowledgement: Mr Jason Cullen for editing the manuscript, Ms. Worachanee Imjaijit for statistical analysis, Ms Ratchadaporn Inunchote for typing the manuscript.

Contributors: TT: designed the study and was involved with data acquisition, analysis and interpretation as well as manuscript preparation; SS: edited the manuscript and made revisions for critically important content; CT and MB: prepared the questions for the formative and summative examinations and edited the manuscript.

Funding: The research fund from Navamindradhiraj University, Bangkok, Thailand. Competing interest: None stated.

*THANANDA TRAKARNVANICH, SUPATSRI SETHASINE, CHARNARONG TRISUWANWAT AND METHAVEE INSAWANG
Department of Medicine, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand. *thananda@hotmail.com

REFERENCES

Ketotic Hypoglycemia in Children with Previous Transient Congenital Hyperinsulinism

Congenital Hyperinsulinism (CHI) is a major cause of neonatal hypoglycemia characterised by non-ketotic hypoglycemia. We describe the occurrence and higher prevalence of ketotic hypoglycemia (KH) in 5 children with transient CHI. Four children had required diazoxide to control the persistent hypoglycemia that was discontinued at a mean age of 11.25 (+5.25) months. KH developed after an average time period of 6.7 months following the resolution of CHI. Children with transient CHI may be at risk of subsequently developing KH at a variable age period.

Keywords: Neonatal hypoglycemia, Ketotic hypoglycemia, Outcome.

Congenital hyperinsulinism (CHI) is a complex genetic disorder causing recurrent and persistent hypoglycemia, affecting 1 in 50,000 children due to defective insulin secretion from pancreatic \( \beta \)-cells [1]. CHI, can be transient or permanent, and could be associated with overgrowth syndromes, birth asphyxia, IUGR, Rh isoimmunisation and maternal diabetes mellitus [2].

Ketotic hypoglycemia (KH) is the most common form of hypoglycemia beyond infancy, the exact etiopatho-genesis of which still remains obscure [3,4]. KH readily responds to oral or intravenous glucose administration without causing permanent neurological sequelae with majority of children outgrowing this condition with age. The development of KH after resolution of transient CHI has not been widely reported. We report our observations on KH after resolution of CHI.

After approval from the Institute’s Ethics Committee the clinical data was collected from 142 children referred to our centre with persistent hypoglycemia between 2009 and 2016. Diagnosis of CHI (inappropriately high insulin and C-peptide and low Free Fatty Acids (FFA) and 3-beta-hydroxybutyrate) and KH (low insulin and C-peptide with elevated FFA, 3-beta-hydroxybutyrate and normal cortisol during hypoglycemia [glucose <45 mg/dL]) were made based on clinical and biochemical parameters. Patients with CHI who developed KH subsequently were included in the study.

Five children (all boys) developed KH subsequent to resolution of CHI. Baseline characteristics of each child and time interval for development of KH are shown in **Web Table I**. The mean (SD) birthweight was 2.82 (0.45) kg and the mean age at the time of initial presentation was 46.8 hours. All patients required higher rates of glucose infusion [13.70 (1.57) mg/kg/min] with a mean (SD) glucose concentration of 1.98 (0.72) mmol/L. The biochemical screen during hypoglycemia confirmed CHI (raised insulin concentration with suppressed FFA and 3-beta-hydroxybutyrate). Four children required Diazoxide [7.38 (1.94) mg/kg/day] therapy which was discontinued at a mean (SD) age of 11.2 (5.25) months. KH developed after a mean duration of 6.7 months following resolution of CHI.
Our study revealed that some infants presenting with transient CHI have an increased risk of developing KH later in childhood. Majority of patients with CHI tend to be of transient nature with some requiring diazoxide therapy for variable time periods [5].

KH is typically seen in toddlers who miss meals owing to inter-current illness and develop hypoglycemia along with ketonemia and ketonuria. In our study, all 5 children presented with KH during intercurrent illness. Christensen described failure of the adrenergic stress response during episodes of KH [6]. One of our patients had low cortisol but his short Synacthen test revealed normal cortisol reserve.

Development of KH exclusively in males was a notable feature of our study; similar to a previous study [9], which showed that children of male gender and with low body weight have increased susceptibility to KH [7]. However, the exact mechanism behind this association; however, is unclear.

IUGR infants are known to be hypoinsulinemic, secondary to placental insufficiency producing diminished transplacental glucose transport which reduces protein and glycogen synthesis. Lower plasma concentrations of insulin and glucose produces a marked reduction in hepatic and muscle glycogen content [8]. The reason why only some newborns with IUGR develop CHI is unclear. Small sample size and retrospective nature were the major limitations of our study.

Patients with transient CHI need long term follow-up to enable early identification and appropriate management of KH.

Contributors: PP: literature search, data collection and manuscript review, act as guarantor; DG: editing the manuscript, managed the patient; MD and SS: acquisition and interpretation of data, managed the patients and edited the manuscript; SS: manuscript review, manuscript editing, drafting the article and revising the article critically for important intellectual content. All authors reviewed and approved the manuscript for publication. PP: will act as guarantor of the study.

Funding: None; Competing interest: None stated.

PRASHANT PATIL, DINESH GIRI, MOHAMMED DIDI AND Senthil Senniappan
*Department of Paediatric Endocrinology, Alder Hey Children’s Hospital, Liverpool, UK.
*senthilkss@yahoo.co.uk

REFERENCES
### WEB TABLE I: Sali ent Features of Children with Ketotic Hypoglycemia Following Congenital Hyperinsulism

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age (wks)</td>
<td>40</td>
<td>37</td>
<td>40</td>
<td>38</td>
<td>41</td>
</tr>
<tr>
<td>Birth weight (SD)</td>
<td>3.05 (0.98)</td>
<td>2.65 (-2.15)</td>
<td>2.8(-1.59)</td>
<td>2.2(-3.06)</td>
<td>3.4(-0.17)</td>
</tr>
<tr>
<td>Age at presentation, h</td>
<td>18</td>
<td>72</td>
<td>72</td>
<td>24</td>
<td>48</td>
</tr>
<tr>
<td>Peak GIR mg/kg/min</td>
<td>12.5</td>
<td>12</td>
<td>14</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td>Treatment</td>
<td>Diazoxide</td>
<td>Polycal</td>
<td>Diazoxide</td>
<td>Diazoxide</td>
<td>Diazoxide</td>
</tr>
<tr>
<td>Age when diazoxide stopped (months)</td>
<td>4</td>
<td>3</td>
<td>16</td>
<td>11</td>
<td>14</td>
</tr>
<tr>
<td>DT</td>
<td>14</td>
<td>7</td>
<td>5</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Glucose, mmol/L</td>
<td>2.2</td>
<td>0.8</td>
<td>2.7</td>
<td>2.3</td>
<td>1.9</td>
</tr>
<tr>
<td>Insulin, mU/L</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
</tr>
<tr>
<td>FFA, µmol/L</td>
<td>2104</td>
<td>3465</td>
<td>2469</td>
<td>2958</td>
<td>5772</td>
</tr>
<tr>
<td>3-hydroxy butyrate, µmol/L</td>
<td>1964</td>
<td>4600</td>
<td>1989</td>
<td>3374</td>
<td>3091</td>
</tr>
<tr>
<td>Cortisol, nmol/L</td>
<td>830</td>
<td>623</td>
<td>498</td>
<td>830</td>
<td>278</td>
</tr>
<tr>
<td>GH, µg/L</td>
<td>8.23</td>
<td>23.2</td>
<td>17.2</td>
<td>9.3</td>
<td>2.59</td>
</tr>
<tr>
<td>Lactate, 0.7-2.1 mmol/L</td>
<td>1.0</td>
<td>1.2</td>
<td>1.4</td>
<td>1.9</td>
<td>1.0</td>
</tr>
</tbody>
</table>

CHI - Congenital Hyperinsulinism; GIR - Glucose Infusion Rate; FFA - Free Fatty Acids, GH - Growth hormone, DT = time interval in months between resolution of CHI and the onset of KH.